Brigatinib (AP26113) Efficacy and Safety in ALK plus NSCLC: Phase 1/2 Trial Results

被引：0

作者：

Gettinger, Scott N. ^{[1
]}

Bazhenova, Lyudmila ^{[2
]}

Salgia, Ravi ^{[3
]}

Langer, Corey J. ^{[4
]}

Gold, Kathryn A. ^{[5
]}

Rosell, Rafael ^{[6
,7
]}

Shaw, Alice ^{[8
]}

Weiss, Glen J. ^{[9
]}

Dorer, David J. ^{[10
]}

Rivera, Victor M. ^{[10
]}

Conlan, Maureen G. ^{[10
]}

Kerstein, David ^{[10
]}

Camidge, Ross ^{[11
]}

机构：

[1] Yale Canc Ctr, New Haven, CT USA

[2] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

[3] Univ Chicago Med, Chicago, IL USA

[4] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Dexeus Univ Inst, Barcelona, Spain

[7] Catalan Inst Oncol, Barcelona, Spain

[8] Massachusetts Gen Hosp, Boston, MA 02114 USA

[9] Canc Treatment Ctr Amer, Goodyear, AZ USA

[10] Ariad Pharmaceut Inc, Cambridge, MA USA

[11] Univ Colorado, Ctr Canc, Aurora, CO USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期

关键词：

NSCLC; TKI; brigatinib;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ORAL33.06

引用

页码：S238 / S239

页数：2

共 50 条

[41] Ablation to Oligo-Residual Sites Plus ICIs Improved Survival of Patients with Advanced NSCLC: Preliminary Results of a Prospective Phase II Trial [J].

Yang, S. ;

Chen, B. ;

Yu, J. ;

Liu, X. ;

Jiang, T. ;

Wu, F. ;

Li, A. ;

Gao, G. ;

Chen, X. ;

Ren, S. .

JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) :S17-S18

[42] Efficacy and Safety of KRAS G12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study [J].

Zhou, Qing ;

Meng, Xiangjiao ;

Sun, Longhua ;

Huang, Dingzhi ;

Yang, Nong ;

Yu, Yan ;

Zhao, Mingfang ;

Zhuang, Wu ;

Guo, Renhua ;

Hu, Yi ;

Pan, Yueyin ;

Shan, Jinlu ;

Sun, Meili ;

Yuan, Ying ;

Fan, Yun ;

Huang, Jianan ;

Liu, Lian ;

Chu, Qian ;

Wang, Xiuwen ;

Xu, Chongrui ;

Lin, Jiaxin ;

Huang, Jingjing ;

Huang, Mengna ;

Sun, Jiya ;

Zhang, Sujie ;

Zhou, Hui ;

Wu, Yi-Long .

JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (12) :1630-1639

[43] Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study [J].

Cho, Byoung Chul ;

Obermannova, Radka ;

Bearz, Alessandra ;

McKeage, Mark ;

Kim, Dong-Wang ;

Batra, Ullas ;

Borra, Gloria ;

Orlov, Sergey ;

Kim, Sang-We ;

Geater, Sarayut L. ;

Postmus, Pieter E. ;

Laurie, Scott A. ;

Park, Keunchil ;

Yang, Cheng-Ta ;

Ardizzoni, Andrea ;

Bettini, Anna C. ;

de Castro, Gilberto, Jr. ;

Kiertsman, Flavia ;

Chen, Zhe ;

Lau, Yvonne Y. ;

Viraswami-Appanna, Kalyanee ;

Passos, Vanessa Q. ;

Dziadziuszko, Rafal .

JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (07) :1255-1265

[44] Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study [J].

Yang, James Chih-Hsin ;

Reckamp, Karen L. ;

Kim, Young-Chul ;

Novello, Silvia ;

Smit, Egbert F. ;

Lee, Jong-Seok ;

Su, Wu -Chou ;

Akerley, Wallace L. ;

Blakely, Collin M. ;

Groen, Harry J. M. ;

Bazhenova, Lyudmila ;

Costa, Enric Carcereny ;

Chiari, Rita ;

Hsia, Te-Chun ;

Golsorkhi, Tony ;

Despain, Darrin ;

Shih, Danny ;

Popat, Sanjay ;

Wakelee, Heather .

JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (02)

[45] Repotrectinib in Patients with ROS1 Fusion-positive (ROS1+) NSCLC: Update from the Pivotal Phase 1/2 TRIDENT-1 Trial [J].

Cho, B. C. ;

Camidge, D. R. ;

Lin, J. J. ;

Kim, S. -W. ;

Solomon, B. ;

Dziadziuszko, R. ;

Besse, B. ;

Goto, K. ;

de Langen, A. J. ;

Wolf, J. ;

Lee, K. H. ;

Popat, S. ;

Springfeld, C. ;

Nagasaka, M. ;

Felip, E. ;

Yang, N. ;

Lu, S. ;

Kao, S. ;

Velcheti, V. ;

Cheema, P. ;

Stopatschinskaja, S. ;

Mehta, M. ;

Trone, D. ;

Ades, F. ;

Calvet, C. Y. ;

Drilon, A. .

JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) :S50-S51

[46] Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report [J].

Ou, Sai-Hong Ignatius ;

Solomon, Benjamin J. ;

Besse, Benjamin ;

Bearz, Alessandra ;

Lin, Chia-Chi ;

Chiari, Rita ;

Camidge, D. Ross ;

Lin, Jessica J. ;

Abbattista, Antonello ;

Toffalorio, Francesca ;

Soo, Ross A. .

JOURNAL OF THORACIC ONCOLOGY, 2025, 20 (04) :513-520

[47] T-DM1 and Osimertinib (TRAEMOS) To Target HER2 Bypass Track Resistance in EGFRm plus NSCLC: Interim Analysis of a Phase II Trial [J].

Jebbink, M. ;

De Langen, A. J. ;

Monkhorst, K. ;

Boelens, M. C. ;

Van den Broek, D. ;

Van der Noort, V. ;

De Gooijer, C. J. ;

Van der Wekken, A. J. ;

Hendriks, L. ;

Hashemi, S. M. S. ;

Paats, M. S. ;

Dingemans, A. ;

Smit, E. .

JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) :S891-S892

[48] Phase 1 Study of Ceritinib 450 mg or 600 mg Taken with a Low-Fat Meal versus 750 mg in Fasted State in ALK plus Metastatic NSCLC [J].

Dziadziuszko, Rafal ;

Kim, Dong-Wan ;

Bearz, Alessandra ;

Laurie, Scott ;

Mckeage, Mark ;

Park, Keunchil ;

Kim, Sang-We ;

Passos, Vanessa Q. ;

Osborne, Karen ;

Lau, Yvonne Y. ;

Gu, Jessie ;

Cho, Byoung Chul .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) :S1184-S1184

[49] Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial [J].

Ahn, Myung-Ju ;

Cho, Byoung Chul ;

Ou, Xiaoling ;

Walding, Andrew ;

Dymond, Angela W. ;

Ren, Song ;

Cantarini, Mireille ;

Janne, Pasi A. .

JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (05) :718-723

[50] Phase 1b Trial of Cabozantinib or Cabozantinib Plus Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) [J].

Lim, F. ;

Ponce, S. ;

Patel, S. ;

Van Herpen, C. ;

Kurkjian, C. ;

Lou, Y. ;

Liu, Y. ;

Ramsingh, G. ;

Pal, S. ;

Neal, J. .

JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) :S405-S406

← 1 2 3 4 5 →